Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma

American Journal of Surgical Pathology

Volumn 33, Issue 8, 2009, Pages 1125-1136

  Rabban, Joseph T ^a   Barnes, Michael ^a   Chen, Lee May ^b   Powell, Catherine B ^b   Crawford, Beth ^c   Zaloudek, Charles J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BRCA; Metastatic breast cancer; Occult ovarian carcinoma; Risk reducing salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; FAMILIAL CANCER; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; OCCULT CANCER; ONCOGENE; OVARY CANCER; OVARY DISEASE; PROPHYLAXIS; RISK REDUCTION; SALPINGOOOPHORECTOMY; UTERINE TUBE; UTERINE TUBE CARCINOMA;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; FALLOPIAN TUBES; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; NEOPLASMS, MULTIPLE PRIMARY; OVARIAN NEOPLASMS; OVARIECTOMY; OVARY; RISK FACTORS;

EID: 68249107855     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31819e986a     Document Type: Article

References (70)

1. Agoff SN, Mendelin JE, Grieco VS, et al. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol. 2002;26:171-178.
2. Aktepe F, Kapucuoglu N, Pak I. The effects of chemotherapy on breast cancer tissue in locally advanced breast cancer. Histopathology. 1996;29:63-67.
3. Alvarado-Cabrero I, Young RH, Vamvakas EC, et al. Carcinoma of the fallopian tube: a clinicopathological study of 105 cases with observations on staging and prognostic factors. Gynecol Oncol. 1999;72:367-379.
4. American Joint Committee on Cancer. AJCC Cancer Staging Manual. New York: Springer-Verlag; 2002.
5. Antila R, Jalkanen J, Heikinheimo O. Comparison of secondary and primary ovarian malignancies reveals differences in their pre- and perioperative characteristics. Gynecol Oncol. 2006;101:97-101.
6. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
7. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet. 1896;2:104-107.
8. Bhargava R, Beriwal S, Dabbs DJ. Mammaglobin versus GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol. 2007;127:103-113.
9. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-3990.
10. Carcangiu ML, Radice P, Manoukian S, et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol. 2004;23:35-40.
11. Carcangiu ML, Peissel B, Pasini B, et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol. 2006;30:1222-1230.
12. Casey MJ, Bewtra C, Hoehne LL, et al. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds. Gynecol Oncol. 2000;78:278-287.
13. Chan J, Fuh K, Shin J, et al. The treatment and outcomes of earlystage epithelial ovarian cancer: have we made any progress? Br J Cancer. 2008;98:1191-1196.
14. Colgan TJ. Challenges in the early diagnosis and staging of Fallopian-tube carcinomas associated with BRCA mutations. Int J Gynecol Pathol. 2003;22:109-120.
15. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25:1283-1289.
16. Crum CP, Drapkin R, Kindelberger D, et al. Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res. 2007;5:35-44.
17. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19:3-9.
18. Demopoulos RI, Touger L, Dubin N. Secondary ovarian carcinoma: a clinical and pathological evaluation. Int J Gynecol Pathol. 1987;6:166-175.
19. Domchek SM, Friebel TM, Neuhausen SL, et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol. 2006;7:223-229.
20. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296:185-192.
21. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64.
22. Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95:681-695.
23. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676-689.
24. Fujiwara K, Ohishi Y, Koike H, et al. Clinical implications of metastases to the ovary. Gynecol Oncol. 1995;59:124-128.
25. Gagnon Y, Tetu B. Ovarian metastases of breast carcinoma. A clinicopathologic study of 59 cases. Cancer. 1989;64:892-898.
26. Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol. 2006;24:4642-4660.
27. Hann LE, Lui DM, Shi W, et al. Adnexal masses in women with breast cancer: US findings with clinical and histopathologic correlation. Radiology. 2000;216:242-247.
28. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. J Epidemiol Biostat. 2001;6:107-138.
29. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-1615.
30. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25:2921-2927.
31. Kennedy S, Merino MJ, Swain SM, et al. The effects of hormonal and chemotherapy on tumoral and nonneoplastic breast tissue. Hum Pathol. 1990;21:192-198.
32. Khunamornpong S, Suprasert P, Chiangmai WN, et al. Metastatic tumors to the ovaries: a study of 170 cases in northern Thailand. Int J Gynecol Cancer. 2006;16(suppl 1):132-138.
33. Laki F, Kirova YM, This P, et al. Prophylactic salpingooophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation. Cancer. 2007;109:1784-1790.
34. Lamb JD, Garcia RL, Goff BA, et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2006;194:1702-1709.
35. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007;107:159-162.
36. Lee BH, Hecht JL, Pinkus JL, et al. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids. Am J Clin Pathol. 2002;117:745-750.
37. Lee Y, Medeiros F, Kindelberger D, et al. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol. 2006;13:1-7.
38. Lee YT, Hori JM. Significance of ovarian metastasis in therapeutic oophorectomy for advanced breast cancer. Cancer. 1971;27: 1374-1378.
39. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87:52-56.
40. Leunen K, Legius E, Moerman P, et al. Prophylactic salpingooophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia. Int J Gynecol Cancer. 2006;16:183-188.
41. Lu KH, Garber JE, Cramer DW, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 2000;18:2728-2732.
42. Lumb G, Mackenzie D. The incidence of metastases in adrenal glands and ovaries removed for carcinoma of the breast. Cancer. 1959;12:521-526.
43. Lynch HT, Lemon SJ, Durham C, et al. A descriptive study of BRCA1 testing and reactions to disclosure of test results. Cancer. 1997;79:2219-2228.
44. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236.
45. Meeuwissen PA, Seynaeve C, Brekelmans CT, et al. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol. 2005;97:476-482.
46. Moll UM, Chumas J. Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer. Pathol Res Pract. 1997;193:187-196.
47. Moore RG, Chung M, Granai CO, et al. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol. 2004;93:87-91.
48. Moritani S, Ichihara S, Hasegawa M, et al. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? Hum Pathol. 2008;39:666-671.
49. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Breast Cancer Risk Reduction. (Version 1. 2009). http://www.nccn.org.
50. Olivier RI, van BM, Lubsen MA, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer. 2004;90:1492-1497.
51. Onuma K, Dabbs DJ, Bhargava R. Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol. 2008;27:418-425.
52. Petru E, Pickel H, Heydarfadai M, et al. Nongenital cancers metastatic to the ovary. Gynecol Oncol. 1992;44:83-86.
53. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingooophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23: 127-132.
54. Puga FJ, Gibbs CP, Williams TJ. Castrating operations associated with metastatic lesions of the breast. Obstet Gynecol. 1973;41: 713-719.
55. Rabban JT, Crawford B, Chen LM, et al. Transitional cell metaplasia of fallopian tube fimbriae: a potential mimic of early tubal carcinoma in risk reduction salpingo-oophorectomies from women with BRCA mutations. Am J Surg Pathol. 2009;33:111-119.
56. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-1622.
57. Rutter JL, Wacholder S, Chetrit A, et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based casecontrol study. J Natl Cancer Inst. 2003;95:1072-1078.
58. Saphir O, Parker ML. Metastasis of primary carcinoma of breast with special references to spleen, adrenal glands and ovaries. Arch Surg. 1941;43:1003.
59. Schlosshauer PW, Cohen CJ, Penault-Llorca F, et al. Prophylactic oophorectomy: a morphologic and immunohistochemical study. Cancer. 2003;98:2599-2606.
60. Skirnisdottir I, Garmo H, Holmberg L. Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990 to 2003: occurrence, origin and survival compared to ovarian cancer. Gynecol Oncol. 2007;105:166-171.
61. Stratton JF, Buckley CH, Lowe D, et al. Comparison of prophylactic oophorectomy specimens from carriers and noncarriers of a BRCA1 or BRCA2 gene mutation. United Kingdom Coordinating Committee on Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. J Natl Cancer Inst. 1999;91:626-628.
62. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
63. Takeda Y, Tsuta K, Shibuki Y, et al. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors. Arch Pathol Lab Med. 2008;132:239-243.
64. Tornos C, Soslow R, Chen S, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol. 2005;29:1482-1489.
65. Turksoy N. Ovarian metastasis of breast carcinoma. Obstet Gynecol. 1960;15:573-578.
66. Ulbright TM, Roth LM, Stehman FB. Secondary ovarian neoplasia. A clinicopathologic study of 35 cases. Cancer. 1984;53:1164-1174.
67. Webb MJ, Decker DG, Mussey E. Cancer metastatic to the ovary: factors influencing survival. Obstet Gynecol. 1975;45:391-396.
68. Woodruff JD, Murthy YS, Bhaskar TN, et al. Metastatic ovarian tumors. Am J Obstet Gynecol. 1970;107:202-209.
69. Yada-Hashimoto N, Yamamoto T, Kamiura S, et al. Metastatic ovarian tumors: a review of 64 cases. Gynecol Oncol. 2003;89: 314-317.
70. Young RH, Carey RW, Robboy SJ. Breast carcinoma masquerading as primary ovarian neoplasm. Cancer. 1981;48:210-212.